Treatment-free survival (TFS) outcomes from the phase II study of nivolumab and salvage nivolumab plus ipilimumab in advanced clear cell renal cell carcinoma (aRCC) (HCRN GU16260-Cohort A).
JOURNAL OF CLINICAL ONCOLOGY（2023）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要